Mycard On December 4 2024 the Food and Drug Administration approved durvalumab Imfinzi AstraZeneca for limited stage small cell lung cancer LS SCLC
The ADRIATIC study marks a major advancement in limited stage small cell lung cancer LS SCLC showing that consolidation therapy with durvalumab after chemoradiation significantly The first interim analysis of the groundbreaking ADRIATIC trial showed that consolidation therapy with the immune checkpoint inhibitor durvalumab Imfinzi was associated with a nearly two
Mycard
Mycard
[img-1]
[img_title-2]
[img-2]
[img_title-3]
[img-3]
AstraZeneca s Imfinzi durvalumab has been recommended for approval in the European Union EU as monotherapy for the treatment of adults with limited stage small cell lung cancer LS KEY POINTS In the phase III ADRIATIC trial durvalumab consolidation improved median overall survival by 22 5 months and progression free survival by 7 4 months compared with placebo
Consolidation therapy with the PD L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited stage small cell lung cancer SCLC compared with In the industry supported phase 3 ADRIATIC trial 730 patients who had completed chemoradiation for limited stage SCLC were randomized to receive durvalumab 1500 mg durvalumab plus
Download Mycard
More picture related to Mycard
[img_title-4]
[img-4]
[img_title-5]
[img-5]
[img_title-6]
[img-6]
ADRIATIC which was designed to assess the role of durvalumab as consolidation therapy following concurrent chemoradiotherapy for patients with limited stage small cell lung cancer After a first interim analysis of the ADRIATIC study significant improvements in overall survival OS and progression free survival PFS were reported with durvalumab versus placebo
Positive high level results of the ADRIATIC Phase III trial showed AstraZeneca s Imfinzi durvalumab demonstrated a statistically significant and clinically meaningful improvement in the [desc-11]
[img_title-7]
[img-7]
[img_title-8]
[img-8]
https://www.fda.gov
On December 4 2024 the Food and Drug Administration approved durvalumab Imfinzi AstraZeneca for limited stage small cell lung cancer LS SCLC
https://www.cell.com
The ADRIATIC study marks a major advancement in limited stage small cell lung cancer LS SCLC showing that consolidation therapy with durvalumab after chemoradiation significantly
[img_title-9]
[img_title-7]
[img_title-10]
[img_title-11]
[img_title-12]
[img_title-13]
[img_title-13]
[img_title-14]
[img_title-15]
[img_title-16]
Mycard - [desc-12]
